A phase I double-blind, randomised, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and immunogenicity of PolyCAb in healthy subjects following single doses and on cohort of multiple dosing
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs PolyCAb (Primary)
- Indications Clostridium infections
- Focus Adverse reactions
- Sponsors MicroPharm
- 09 Mar 2017 Planned End Date changed from 31 Dec 2016 to 31 Mar 2017.
- 09 Mar 2017 Status changed from completed to active, no longer recruiting.
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.